Cancers, Vol. 10, Pages 289: miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy

Cancers, Vol. 10, Pages 289: miRNA-205 Nanoformulation Sensitizes Prostate Cancer Cells to Chemotherapy

Cancers doi: 10.3390/cancers10090289

Authors: Prashanth K. B. Nagesh Pallabita Chowdhury Elham Hatami Vijaya K. N. Boya Vivek K. Kashyap Sheema Khan Bilal B. Hafeez Subhash C. Chauhan Meena Jaggi Murali M. Yallapu

The therapeutic application of microRNA(s) in the field of cancer has generated significant attention in research. Previous studies have shown that miR-205 negatively regulates prostate cancer cell proliferation, metastasis, and drug resistance. However, the delivery of miR-205 is an unmet clinical need. Thus, the development of a viable nanoparticle platform to deliver miR-205 is highly sought. A novel magnetic nanoparticle (MNP)-based nanoplatform composed of an iron oxide core with poly(ethyleneimine)-poly(ethylene glycol) layer(s) was developed. An optimized nanoplatform composition was confirmed by examining the binding profiles of MNPs with miR-205 using agarose gel and fluorescence methods. The novel formulation was applied to prostate cancer cells for evaluating cellular uptake, miR-205 delivery, and anticancer, antimetastasis, and chemosensitization potentials against docetaxel treatment. The improved uptake and efficacy of formulations were studied with confocal imaging, flow cytometry, proliferation, clonogenicity, Western blot, q-RT-PCR, and chemosensitization assays. Our findings demonstrated that the miR-205 nanoplatform induces significant apoptosis and enhancing chemotherapeutic effects in prostate cancer cells. Overall, these study results provide a strong proof-of-concept for a novel nonviral-based nanoparticle protocol for effective microRNA delivery to prostate cancer cells.

https://ift.tt/2BLexfd